000124369 001__ 124369
000124369 005__ 20240228145509.0
000124369 0247_ $$2doi$$a10.1002/jcsm.12165
000124369 0247_ $$2pmid$$apmid:27896952
000124369 0247_ $$2pmc$$apmc:PMC5377413
000124369 0247_ $$2ISSN$$a2190-5991
000124369 0247_ $$2ISSN$$a2190-6009
000124369 0247_ $$2altmetric$$aaltmetric:16372900
000124369 037__ $$aDKFZ-2017-01248
000124369 041__ $$aeng
000124369 082__ $$a610
000124369 1001_ $$aKlassen, Oliver$$b0
000124369 245__ $$aMuscle strength in breast cancer patients receiving different treatment regimes.
000124369 260__ $$aHoboken, NJ$$bWiley$$c2017
000124369 3367_ $$2DRIVER$$aarticle
000124369 3367_ $$2DataCite$$aOutput Types/Journal article
000124369 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1525074556_11537
000124369 3367_ $$2BibTeX$$aARTICLE
000124369 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000124369 3367_ $$00$$2EndNote$$aJournal Article
000124369 500__ $$aScharhag-Rosenberger, F, Sorkin, M not imported
000124369 520__ $$aMuscle dysfunction and sarcopenia have been associated with poor performance status, an increased mortality risk, and greater side effects in oncologic patients. However, little is known about how performance is affected by cancer therapy. We investigated muscle strength in breast cancer patients in different adjuvant treatment settings and also compared it with data from healthy individuals.Breast cancer patients (N = 255) from two randomized controlled exercise trials, staged 0-III and aged 54.4 ± 9.4 years, were categorized into four groups according to their treatment status. In a cross-sectional design, muscle function was assessed bilaterally by isokinetic dynamometry (0°, 60°, 180°/s) as maximal voluntary isometric contraction (MVIC) and maximal isokinetic peak torque (MIPT) in shoulder rotators and knee flexors and extensors. Additionally, muscular fatigue index (FI%) and shoulder flexibility were evaluated. Healthy women (N = 26), aged 53.3 ± 9.8 years, were tested using the same method. Analysis of covariance was used to estimate the impact of different cancer treatments on skeletal muscle function with adjustment for various clinical and socio-demographic factors.Consistently, lower muscle strength was measured in shoulder and knee strength in patients after chemotherapy. On average, patients had up to 25% lower strength in lower extremities and 12-16% in upper extremities in MVIC and MIPT during cancer treatment compared with healthy women. No substantial difference between patient groups in shoulder strength, but significantly lower shoulder flexibility in patients with radical mastectomy was measured. Chemotherapy-treated patients had consistently higher FI%. No serious adverse events were reported.Breast cancer patients showed markedly impaired muscle strength and joint dysfunctions before and after anticancer treatment. The significant differences between patients and healthy individuals underline the need of exercise therapy as early as possible in order to prevent or counteract the loss of muscle function after curative surgery as well as the consequences of neo-/adjuvant chemotherapy.
000124369 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000124369 588__ $$aDataset connected to CrossRef, PubMed,
000124369 7001_ $$0P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aSchmidt, Martina$$b1
000124369 7001_ $$0P:(DE-He78)9fcfe1306c0e35afdc4503b65f496834$$aScharhag-Rosenberger, Friederike$$b2$$udkfz
000124369 7001_ $$aUlrich, Cornelia M$$b3
000124369 7001_ $$aSchneeweiss, Andreas$$b4
000124369 7001_ $$aPotthoff, Karin$$b5
000124369 7001_ $$0P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aSteindorf, Karen$$b6$$eLast author
000124369 7001_ $$00000-0002-5971-5436$$aWiskemann, Joachim$$b7$$eLast author
000124369 773__ $$0PERI:(DE-600)2586864-0$$a10.1002/jcsm.12165$$gVol. 8, no. 2, p. 305 - 316$$n2$$p305 - 316$$tJournal of cachexia, sarcopenia and muscle$$v8$$x2190-5991$$y2017
000124369 909CO $$ooai:inrepo02.dkfz.de:124369$$pVDB
000124369 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)2def8f8594c8f797f5ed4398258c6cac$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000124369 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9fcfe1306c0e35afdc4503b65f496834$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000124369 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)a0c2037d9054be26907a05ae520d5756$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000124369 9101_ $$0I:(DE-588b)2036810-0$$60000-0002-5971-5436$$aDeutsches Krebsforschungszentrum$$b7$$kDKFZ
000124369 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000124369 9141_ $$y2017
000124369 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000124369 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000124369 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000124369 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000124369 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ
000124369 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ CACHEXIA SARCOPENI : 2015
000124369 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000124369 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000124369 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000124369 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bJ CACHEXIA SARCOPENI : 2015
000124369 9201_ $$0I:(DE-He78)G210-20160331$$kG210$$lBewegung, Präventionsforschung und Krebs$$x0
000124369 980__ $$ajournal
000124369 980__ $$aVDB
000124369 980__ $$aI:(DE-He78)G210-20160331
000124369 980__ $$aUNRESTRICTED